Targeted drugs and immunotherapies are among the advances that contribute to declines in incidence and deaths from non-small cell lung cancer, according to the Annual Report to the Nation on the Status of Cancer. But the trends are on the rise for some other cancers and racial disparities persist, highlighting the need to better understand these differences.
